Patient characteristics of the discovery cohort and the independent validation cohort
| . | Discovery cohort . | Independent validation cohort . | ||||
|---|---|---|---|---|---|---|
| Patient characteristics . | Number of patients (%) (n = 82) . | Progression (%) (n = 31) . | Nonprogression (%) (n = 51) . | Number of patients (%) (n = 72) . | Progression (%) (n = 20) . | Nonprogression (%) (n = 52) . |
| Sex | ||||||
| Male | 54 (66) | 19 (61) | 35 (69) | 38 (53) | 10 (50) | 28 (54) |
| Female | 28 (34) | 12 (39) | 16 (31) | 34 (47) | 10 (50) | 24 (46) |
| Age | ||||||
| <60 | 26 (32) | 6 (19) | 13 (25) | 30 (42) | 9 (45) | 21 (40) |
| ≥60 | 56 (68) | 25 (81) | 38 (75) | 42 (58) | 11 (55) | 31 (60) |
| Clinical stage | ||||||
| IA | 29 (35) | 11 (35) | 18 (35) | 42 (58) | 4 (20) | 38 (73) |
| IB | 52 (63) | 20 (65) | 32 (63) | 29 (40) | 15 (75) | 14 (27) |
| IIA | 1 (2) | 0 | 1 (2) | 1 (1) | 1 (5) | 0 |
| T-stage | ||||||
| T1 | 29 (35) | 11 (35) | 18 (35) | 42 (58) | 4 (20) | 38 (73) |
| T1a | 5 | 0 | 5 | 15 | 0 | 15 |
| T1b | 24 | 11 | 13 | 27 | 4 | 23 |
| T2 | 53 (65) | 20 (65) | 33 (65) | 30 (42) | 16 (80) | 14 (27) |
| T2a | 4 | 1 | 3 | 1 | 1 | 0 |
| T2b | 49 | 19 | 30 | 29 | 15 | 14 |
| CLIPi* | ||||||
| 1. Low risk | 10 (12) | 3 (10) | 7 (14) | 19 (26) | 4 (20) | 15 (29) |
| 2. Intermediate risk | 32 (39) | 11 (35) | 21 (41) | 30 (42) | 8 (40) | 22 (42) |
| 3. High risk | 40 (49) | 17 (55) | 23 (45) | 23 (32) | 8 (40) | 15 (29) |
| Treatment† | ||||||
| No treatment | 57 (70) | 22 (71) | 35 (69) | 59 (82) | 14 (70) | 41 (79) |
| Topical treatment | 25 (30) | 9 (29) | 16 (31) | 13 (18) | 6 (30) | 11 (21) |
| . | Discovery cohort . | Independent validation cohort . | ||||
|---|---|---|---|---|---|---|
| Patient characteristics . | Number of patients (%) (n = 82) . | Progression (%) (n = 31) . | Nonprogression (%) (n = 51) . | Number of patients (%) (n = 72) . | Progression (%) (n = 20) . | Nonprogression (%) (n = 52) . |
| Sex | ||||||
| Male | 54 (66) | 19 (61) | 35 (69) | 38 (53) | 10 (50) | 28 (54) |
| Female | 28 (34) | 12 (39) | 16 (31) | 34 (47) | 10 (50) | 24 (46) |
| Age | ||||||
| <60 | 26 (32) | 6 (19) | 13 (25) | 30 (42) | 9 (45) | 21 (40) |
| ≥60 | 56 (68) | 25 (81) | 38 (75) | 42 (58) | 11 (55) | 31 (60) |
| Clinical stage | ||||||
| IA | 29 (35) | 11 (35) | 18 (35) | 42 (58) | 4 (20) | 38 (73) |
| IB | 52 (63) | 20 (65) | 32 (63) | 29 (40) | 15 (75) | 14 (27) |
| IIA | 1 (2) | 0 | 1 (2) | 1 (1) | 1 (5) | 0 |
| T-stage | ||||||
| T1 | 29 (35) | 11 (35) | 18 (35) | 42 (58) | 4 (20) | 38 (73) |
| T1a | 5 | 0 | 5 | 15 | 0 | 15 |
| T1b | 24 | 11 | 13 | 27 | 4 | 23 |
| T2 | 53 (65) | 20 (65) | 33 (65) | 30 (42) | 16 (80) | 14 (27) |
| T2a | 4 | 1 | 3 | 1 | 1 | 0 |
| T2b | 49 | 19 | 30 | 29 | 15 | 14 |
| CLIPi* | ||||||
| 1. Low risk | 10 (12) | 3 (10) | 7 (14) | 19 (26) | 4 (20) | 15 (29) |
| 2. Intermediate risk | 32 (39) | 11 (35) | 21 (41) | 30 (42) | 8 (40) | 22 (42) |
| 3. High risk | 40 (49) | 17 (55) | 23 (45) | 23 (32) | 8 (40) | 15 (29) |
| Treatment† | ||||||
| No treatment | 57 (70) | 22 (71) | 35 (69) | 59 (82) | 14 (70) | 41 (79) |
| Topical treatment | 25 (30) | 9 (29) | 16 (31) | 13 (18) | 6 (30) | 11 (21) |